Seclidemstat mesylate (SP-2577) is a highly effective and reversible inhibitor of KDM1A (LSD1), with a Ki of 31 nM and an IC 50 of 13 nM. It demonstrates significant potential in promoting antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, while also exhibiting inhibitory effects on virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate is a valuable tool for studying Ewing Sarcoma in research settings.

LSD1:13 nM (IC50), LSD1:31 nM (Ki)

Seclidemstat (72 hours) mesylate inhibits SWI/SNF-mutation-dependent tumor cell proliferation with IC 50 ranging from 0.013 to 2.819 μM (COV434, BIN67, SCCOHT-1, TOV21G, SKOV3, A427, H522, A549, H1299, G401, G402, HCC15 cells)[2]. Seclidemstat (72 hours) mesylate promotes endogenous retroviruses (ERVs) expression and activation of IFNβ pathway in SCCOHT cell lines (SCCOHT-1, BIN67, and COV434 cells)[2]. Seclidemstat (3 μM) mesylate promotes PD-L1 expression in SCCOHT COV 434 pIND 20 BRG1-2.7 cell line[2].